GenSci140 for advanced solid tumors

A Multi-center, Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Efficacy of GenSci140 in Patients With Advanced Solid Tumors

This Phase 1 test will try GenSci140 to see if it is safe and shows early signs of benefit in adults with advanced solid tumors, including FRα-positive ovarian cancer.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 170 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. (industry)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 1 site (Shenyang, Liaoning)
• Trial ID: NCT07251166 on ClinicalTrials.gov

What this trial studies

This first-in-human, open-label Phase 1 study in China uses a dose-escalation part to identify the maximum tolerated dose (if any) and recommended dose, followed by a dose-expansion part to assess activity at selected dose levels. Adults with advanced solid tumors, particularly FRα-positive ovarian cancer, will receive GenSci140 and provide fresh or archived tumor tissue for central testing. Investigators will monitor safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity using measurable lesions. The trial enrolls participants aged 18–75 with ECOG 0–1 and adequate organ and cardiac function.

Who should consider this trial

Good fit: Adults 18–75 with advanced solid tumors who have ECOG performance status 0–1, at least one evaluable or measurable lesion, adequate organ function, and willingness to provide tumor tissue are the intended participants.

Not a fit: Patients with ECOG ≥2, life expectancy under three months, unresolved high-grade toxicities from prior therapy, significant uncontrolled cardiac disease, or inadequate organ function are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, GenSci140 could provide a new treatment option for people with advanced or FRα-positive tumors that have limited standard therapies.

How similar studies have performed: Related early-phase programs targeting folate receptor alpha or using novel targeted agents have shown some promising activity in ovarian cancer but results have been mixed and many approaches remain experimental.

Eligibility criteria

Inclusion Criteria:

1. Those who are able to understand and willing to sign written Informed Consent Form.
2. Aged between 18 and 75 years (inclusive) when signing the ICF
3. Participants with advanced solid tumors
4. The participant agrees to provide fresh biopsy or archived tumor tissues for testing by the central laboratory.
5. At least one evaluable lesion in the dose-escalation part, and at least one measurable lesion in the dose-expansion part.
6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
7. Life expectancy ≥ 3 months.
8. Adequate hematologic and organ function before the first dose of GenSci140.
9. All toxicities related to prior anti-tumor therapies must have resolved to Grade ≤ 1, with the following exceptions: alopecia, peripheral neurotoxicity (must have resolved to Grade ≤ 2).
10. For participants with congestive heart failure (CHF), it must be Grade ≤ 1 in severity and must have recovered completely prior to enrollment.
11. Normal QT interval on electrocardiogram (ECG) evaluation at screening
12. Participants who test negative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).
13. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result. WOCBP must agree to avoid pregnancy.
14. Men with female partners of childbearing potential must take appropriate precautions to avoid pregnancy of partner and use appropriate barrier contraceptives or abstinence

Exclusion Criteria:

1. Past history of cancers.
2. Symptomatic primary central nervous system (CNS) tumors, metastases, leptomeningeal carcinomatosis, or therapy naive spinal cord compression.
3. Use of an investigational medicinal product (IMP) or antitumor therapy (including chemotherapy, biologic therapy, immunotherapy) within 5 half-lives or 4 weeks before the first dose of GenSci140. Concomitant anti-tumor therapy is not permitted
4. Major surgery within 4 weeks prior to the first dose of GenSci140.
5. Radiotherapy for ≥ 20% of bone marrow or large area of radiotherapy within 4 weeks prior to the first dose of GenSci140. Or participants have not recovered from acute effects of radiotherapy to baseline prior to the first dose of GenSci140.
6. Clinically significant active cardiovascular disorder or history of myocardial infarction within 6 months prior to the first dose of GenSci140.
7. Uncontrolled active systemic bacterial, viral, or fungal infection or ongoing serious systemic disease, such as hypertension or diabetes, despite Best Supportive Care. Chronic disease screening is not required.
8. History of multiple sclerosis or other demyelinating diseases, Eaton-Lambert syndrome (paraneoplastic syndrome), alcoholic liver disease, history of internal haemorrhage or ischemic stroke within the past 6 months, haemorrhagic diathesis that are unsuitable for enrollment as assessed by the investigator.
9. Suspected treatment-related pneumonitis that was clinically diagnosed in the past and currently requires steroids or cannot be ruled out by imaging at screening.
10. Uncontrolled pleural effusion, pericardial effusion, or abdominal and pelvic fluid collection requiring drainage and/or diuretics within 14 days prior to the first dose of GenSci140.
11. Pregnant or lactating women.
12. Known hypersensitivity to prior monoclonal antibody therapy.
13. Patients who previously underwent allogeneic or autologous bone marrow transplantation.
14. Participants whom the investigator deems unsuitable for enrollment in this clinical study

Where this trial is running

Shenyang, Liaoning

• The First Hospital of China Medical University — Shenyang, Liaoning, China (RECRUITING)

Study contacts

• Study coordinator: Wen Xu

Conditions: Advanced Solid Tumors